Eribulin mesylate: A promising new antineoplastic agent for locally advanced or metastatic breast cancer

Future Oncology

Volumn 7, Issue 3, 2011, Pages 355-364

  Cortes, Javier ^b   Lorca, Rebeca ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

chemotherapy; efficacy; eribulin mesylate; metastatic breast cancer; nontaxane microtubule dynamics inhibitor; tolerability; tubulin targeted agents

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; ERIBULIN; KETOCONAZOLE; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE;

ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INHIBITION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; IC 50; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAXIMUM PLASMA CONCENTRATION; METASTATIC BREAST CANCER; MICROTUBULE ASSEMBLY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STRUCTURE ACTIVITY RELATION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; FEMALE; FURANS; HUMANS; KETONES; MESYLATES; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 79953152351     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.186     Document Type: Article

References (54)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Porter P: Westernising women's risks? Breast cancer in lower-income countries. N. Engl. J. Med. 358, 213-216 (2008).
3. Gonzalez-Angulo AM, Morales-Vasquez F, ortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv. Exp. Med. Biol. 608, 1-22 (2007).
4. Colozza M, de Azambuja E, Personeni N, Lebrun F, Piccart MJ, Cardoso F: Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 12, 253-270 (2007). (Pubitemid 46556792)
5. Pasquier E, Kavallaris M: Microtubules: a dynamic target in cancer therapy. IUBMB Life 60, 165-170 (2008).
6. Fojo T, Menefee M: Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann. Oncol. 18(Suppl. 5), V3-V8 (2007).
7. Kavallaris M, Annereau JP, Barret JM: Potential mechanisms of resistance to microtubule inhibitors. Semin. Oncol. 35, S22-S27 (2008). (Pubitemid 351758950)
8. Moreno-Aspitia A, Perez EA: Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin. Proc. 84, 533-545 (2009).
9. Martin M, Ruiz A, Munoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the Phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 8, 219-225 (2007). (Pubitemid 46291704)
10. Miller KD, Chap LI, Holmes FA, et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792-799 (2005). (Pubitemid 46224178)
11. Keller AM, Mennel RG, Georgoulias VA, et al. Randomized Phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J. Clin. Oncol. 22, 3893-3901 (2004). (Pubitemid 41079870)
12. Ershler WB: Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 11, 325-335 (2006).
13. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25, 3407-3414 (2007). (Pubitemid 47310876)
14. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS- 247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 25, 3399-3406 (2007). (Pubitemid 47310875)
15. Jordan MA, Kamath K: How do microtubule-targeted drugs work? An overview. Curr. Cancer Drug Targets 7, 730-742 (2007).
16. Swain SM, Arezzo JC: Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin. Adv. Hematol. Oncol. 6, 455-467 (2008).
17. Taxol (paclitaxel), package insert. Bristol- Myers Squibb Company. Ixampra Kit (ixabepilone), prescribing information. Baxter Oncology GmbH, Halle/Westfalen, Germany (2007).
18. Hennenfent KL, Govindan R: Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 17, 735-749 (2006).
19. Zhou XJ, Rahmani R: Preclinical and clinical pharmacology of vinca alkaloids. Drugs 44(Suppl. 4), 1-16 (1992). (Pubitemid 23025990)
20. ABRAXANE®, prescribing information. Abraxis Bioscience Inc. (2007).
21. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 7794-7803 (2005). (Pubitemid 46657376)
22. Hirata Y, Uemura D: Halichondrins: antitumor polyether macrolides from a marine sponge. Pure Appl. Chem. 58, 701-710 (1986). (Pubitemid 16557441)
23. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E: Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 266, 15882-15889 (1991). (Pubitemid 21907740)
24. Aicher TD, Buszek KR, Fang FG, et al. Total synthesis of halichondrin B and norhalichondrin B. J. Am. Chem. Soc. 114, 3162-3164 (1992).
25. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61, 1013-1021 (2001). (Pubitemid 32174419)
26. Kuznetsov G, TenDyke K, Yu MJ, Littlefield BA: Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Proc. Am. Assoc. Cancer Res. 48, 275 (2007).
27. Yu MJ, Kishi Y, Littlefield BA: Discovery of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B. In: Anticancer Agents from Natural Products. Cragg GM, Kingston DGI, Newman DJ (Eds). Taylor & Francis Group (CRC Press), FL, USA, 241-265 (2005).
28. Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol. Pharmacol. 70, 1866-1875 (2006). (Pubitemid 44771902)
29. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086-1095 (2005). (Pubitemid 41079102)
30. Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 64, 5760-5766 (2004). (Pubitemid 39095575)
31. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA: Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol. Cancer Ther. 7, 2003-2011 (2008).
32. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49, 1331-1337 (2010).
33. Alday PH, Correia JJ: Macromolecular interaction of halichondrin B analogs eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation. Biochemistry 48, 7927-7938 (2009).
34. Synold TW, Morgan RJ, Newman EM, et al. A Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial. J. Clin. Oncol. 23, Abstract 3036 (2005).
35. Newman S: Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Curr. Opin. Investig. Drugs 8, 1057-1066 (2007). (Pubitemid 350224331)
36. Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors. Clin. Cancer Res. 15, 4213-4218 (2009).
37. Goel S, Mita AC, Mita M, et al. A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid tumors. Clin. Cancer Res. 15, 4207-4212 (2009).
38. Wong N, Desjardins C, Silberman S, Lewis M: Pharmacokinetics (PK) of E7389, a Halichodrin B analog with novel anti-tubulin activity: results of two Phase I studies with different schedules of administration. J. Clin. Oncol. 23, Abstract 2013 (2005).
39. Minami H, Mukohara T, Nagai S, Mukai H, Namiki M: A Phase I study of eribulin mesylate (E7389) in patients with refractory cancers. Eur. J. Cancer Suppl. 6, Abstract 446 (2008).
40. Zhang ZY, King BM, Pelletier RD, Wong YN: Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother. Pharmacol. 62, 707-716 (2008).
41. Devriese LA, Wanders J, Jenner A, et al. Eribulin mesylate phamacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET). Presented at: 22nd EORTC-AACR-NCI Meeting. Berlin, Germany, 16-19 November 2010.
42. Witteveen P, Marchetti S, Mergui-Roelvink M, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment. J. Clin. Oncol. 28(15), Abstract 2582 (2010).
43. Swami U, Petrylak DP, Raftopoulos H, et al. Phase Ib study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors. J. Clin. Oncol. 28(15), Abstract 2589 (2010).
44. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 27, 2954-2961 (20-9).
45. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 28, 3922-3928 (2010).
46. Iwata H, Aogi K, Masuda N, et al. Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer. J. Clin. Oncol. 28(15), Abstract 1081 (2010).
47. Twelves C, Loesch D, Blum JL, et al. A Phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 28, Abstract CRA1004 (2010).
48. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA: Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin. Breast Cancer 10, 160-163 (2010).
49. Economist Intelligence Unit Limited: Breakaway: the global burden of cancer - challenges and opportunities (2009) http://livestrongblog.org/ GlobalEconomicImpact.pdf
50. Garcia M, Jemal A, Ward EM, et al. Global cancer facts & figures 2007 (2009) www.cancer.org/downloads/STT/Global- Facts-and-Figures-2007-rev2.pdf
51. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology V.1.2010 (2009) www.nccn.org/professionals/physician-gls/PDF/breast. pdf
52. Eisai Inc. Halaven Prescibing Information (2010) www.halaven.com
53. E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer (NCT00388726) http://clinicaltrials.gov/ ct2/show/NCT0038 8726?term=NCT00388726&rank=1
54. E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes (NCT00337103) http://clinicaltrials.gov/ct2/show/NCT00337 103?term=NCT00337103&rank=1